Discover 2,591 paid clinical trials in Illinois. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Illinois offers various clinical research options, including those for healthy volunteers interested in paid studies, as well as for individuals with specific health conditions. Leading research centers in Chicago, Plainfield, and Springfield are actively seeking participants, providing access to innovative treatments and personalized care.
Filter
1
Filter results
Results: 2,591
Case Management Dyad
for
HIV, Pre-exposure Prophylaxis, Case Management,
Location: Chicago IL
Sponsor: University of Chicago
Sex: All
Age: 18+
Code: NCT06162897
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Location: Philadelphia PA, Cleveland OH, Nashville TN, Denver CO,
Sponsor: InSilico Medicine Hong Kong Limited
Sex: All
Age: 18+
Code: NCT06566079
Phase 1, Phase 2, Recruiting
Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval Study
for
Obstructive Sleep Apnea (OSA)
Location: Rochester NY, Bradenton FL, Chicago IL, Kansas City KS,
Sponsor: Inspire Medical Systems, Inc.
Sex: All
Age: 18+
Code: NCT07113288
Recruiting
Trial to Compare the Effects of Myo Munchee Therapy and Oral Motor Therapy (OMT) in Pediatric Patients to Treat Maxillary Deficiency and Orofacial Myofunctional Dysfunction (OMD).
for
Orofacial Myofunctional Disorders, Myo Munchee,
Location: Chicago IL
Sponsor: Myo Munchee (Operations) Pty Ltd
Sex: All
Age: 3 - 5
Code: NCT07088055
Recruiting
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
for
Head and Neck Squamous Cell Carcinoma,
Location: Damariscotta ME, Bath ME, Augusta ME, Brunswick ME,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT06992427
Phase 3, Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer